Sutimlimab

Therapeutic indications

Sutimlimab is indicated for:

Haemolytic anaemia in patients with cold agglutinin disease (CAD)

Population group: only adults (18 years old or older)

Cold autoimmune haemolytic anaemia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

6,500 mg for patients weighing 39-75 kg and 7,500 mg for patients weighing ≥75 kg, weekly for the first two weeks and every two weeks thereafter

Contraindications

Sutimlimab is contraindicated in the following cases:

Active infections

Infectious disease

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.